Adaptive Biotechnologies Corporation - Common Stock (ADPT)
13.78
-0.72 (-4.97%)
NASDAQ · Last Trade: May 5th, 7:50 PM EDT
Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidancechartmill.com
Via Chartmill · May 5, 2026
Get insights into the top gainers and losers of Tuesday's after-hours session.chartmill.com
Via Chartmill · May 5, 2026
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring.
Via The Motley Fool · May 4, 2026
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.
Via The Motley Fool · April 20, 2026
Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitabilitychartmill.com
Via Chartmill · February 5, 2026
This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships.
Via The Motley Fool · April 18, 2026

This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale.
Via The Motley Fool · April 8, 2026

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains.
Via The Motley Fool · March 30, 2026

Adaptive Biotechnologies, a leader in immune-driven diagnostics, saw a notable insider sale amid ongoing innovation in disease monitoring.
Via The Motley Fool · March 26, 2026

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year stock performance.
Via The Motley Fool · March 26, 2026
Adaptive Biotech (ADPT) Earnings Call Transcript
Via The Motley Fool · February 5, 2026
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that blew past Wall Street expectations. The report highlighted a dramatic acceleration in the adoption of its clonoSEQ diagnostic test, positioning the company as a
Via MarketMinute · January 13, 2026
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp wave of year-end tax-loss harvesting has sent many mid-cap and commercial-stage biotech firms into a tailspin. Investors, eager
Via MarketMinute · December 30, 2025
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam Therapeutics.
Via Benzinga · November 4, 2025
Via Benzinga · October 13, 2025
Via Benzinga · September 30, 2025
Via Benzinga · September 30, 2025
Adaptive Biotechnologies (ADPT) aligns with Minervini's trend and high-growth momentum strategies, showing strong technicals, rising earnings, and revenue growth. A top pick for trend investors.
Via Chartmill · August 9, 2025
One of the company's businesses is particularly hot at the moment.
Via The Motley Fool · August 6, 2025
Via Benzinga · August 5, 2025
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.
Via Benzinga · July 26, 2025